Date: 2012-07-18
Type of information: R&D agreement
Compound: immunomodulatory approach to treat type 1 diabetes
Company: Sanofi (France) Brigham and Women's Hospital (USA)
Therapeutic area: Metabolic diseases
Type agreement: R&D
Action mechanism:
Disease: type 1 diabetes
Details: Sanofi has announced a new research collaboration with Brigham and Women\'s Hospital (BWH), a teaching and research affiliate of Harvard Medical School, focused on immunology of type 1 diabetes. The two organizations will share knowledge and apply their respective expertise in basic and applied research regarding diabetes and drug target and candidate development.
Under the terms of the agreement, researchers from both organizations will undertake proof-of-concept, safety and functional studies for a novel immunomodulatory approach to treat type 1 diabetes. Sanofi has an option to exclusively license intellectual property emerging from this collaboration.
This is the third agreement that concludes this year Sanofi in diabetes. Sanofi has already signed two cooperation agreements in diabetes with U.S. research institutions since the beginning of the year. These agreements were concluded with the UCSF and with the Joslin Diabetes Center.
Financial terms: Financial details of the collaboration were not disclosed.
Latest news:
